Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
12 2021
Historique:
revised: 19 08 2021
received: 08 04 2021
accepted: 04 09 2021
pubmed: 1 10 2021
medline: 22 3 2022
entrez: 30 9 2021
Statut: ppublish

Résumé

The importance of iron deficiency (ID) in heart failure with preserved ejection fraction (HFpEF) is unknown. In HF with reduced ejection fraction (HFrEF), ID is reported as an independent predictor of mortality in HF although not all published studies agree. Different definitions of ID have been assessed, and the natural history of untreated ID not established, which may explain the conflicting results. This study aimed to assess the relationship between ID and mortality in HFpEF, clarify which definition of ID correlates best with outcomes in HFrEF, and determine the prognostic importance of change in ID status over time. Analyses were conducted on data from 1563 patients participating in a prospective international cohort study comparing HFpEF with HFrEF. Plasma samples from baseline and 6 month visits were analysed for the presence of ID. Two ID definitions were evaluated: ID Iron deficiency is equally prevalent in HFpEF and HFrEF but is negatively prognostic only in HFrEF. The natural history of ID is important; persistent ID is strongly associated with mortality whereas resolution is not. ID

Identifiants

pubmed: 34592056
doi: 10.1002/ehf2.13617
pmc: PMC8712912
doi:

Substances chimiques

Iron E1UOL152H7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4572-4583

Informations de copyright

© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Open Heart. 2019 Apr 3;6(1):e001012
pubmed: 31168385
Eur Heart J. 2013 Mar;34(11):827-34
pubmed: 23178646
Am Heart J. 2013 Apr;165(4):575-582.e3
pubmed: 23537975
Cardiology. 2014;128(4):320-6
pubmed: 24924145
BMC Cardiovasc Disord. 2018 Nov 1;18(1):206
pubmed: 30382817
ESC Heart Fail. 2021 Dec;8(6):4572-4583
pubmed: 34592056
Heart. 2015 Apr;101(8):592-9
pubmed: 25539945
Eur Heart J. 2010 Aug;31(15):1872-80
pubmed: 20570952
Int J Cardiol. 2018 Jun 15;261:114-118
pubmed: 29580659
Int J Cardiol. 2017 Sep 15;243:360-366
pubmed: 28511855
Eur Heart J. 2015 Mar 14;36(11):657-68
pubmed: 25176939
J Am Coll Cardiol. 2008 Jan 15;51(2):103-12
pubmed: 18191732
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Eur J Heart Fail. 2018 Jan;20(1):125-133
pubmed: 28436136
Circ Heart Fail. 2011 Sep;4(5):599-606
pubmed: 21705484
Int J Cardiol. 2016 Feb 15;205:6-12
pubmed: 26705670
Eur J Heart Fail. 2014 Oct;16(10):1125-32
pubmed: 25208495
Eur Heart J. 2014 Sep 21;35(36):2468-76
pubmed: 24927731
N Engl J Med. 2009 Dec 17;361(25):2436-48
pubmed: 19920054
Circulation. 2017 Aug 8;136(6):e137-e161
pubmed: 28455343
J Am Coll Cardiol. 2011 Sep 13;58(12):1241-51
pubmed: 21903058
Eur J Heart Fail. 2014 Sep;16(9):984-91
pubmed: 25065368
Eur Heart J. 2018 May 21;39(20):1770-1780
pubmed: 29390051
Int J Cardiol. 2015 Sep 15;195:143-8
pubmed: 26043148
Circ Heart Fail. 2018 Feb;11(2):e004519
pubmed: 29382661

Auteurs

Sarah Fitzsimons (S)

Heart Health Research Group, University of Auckland, Auckland, New Zealand.

Tee Joo Yeo (TJ)

Cardiovascular Research Institute, National University Health System, Singapore.
National University Heart Centre Singapore, Singapore.

Lieng H Ling (LH)

Cardiovascular Research Institute, National University Health System, Singapore.
National University Heart Centre Singapore, Singapore.

David Sim (D)

National University Heart Centre Singapore, Singapore.

Kui Toh Gerard Leong (KTG)

Changi General Hospital, Singapore.

Poh Shuan Daniel Yeo (PSD)

Tan Tock Seng Hospital, Singapore.

Hean Yee Ong (HY)

Khoo Teck Puat Hospital, Singapore.

Fazlur Jaufeerally (F)

Singapore General Hospital, Singapore.

Tze P Ng (TP)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Katrina Poppe (K)

Heart Health Research Group, University of Auckland, Auckland, New Zealand.

Mayanna Lund (M)

Middlemore Hospital, Auckland, New Zealand.

Gerry Devlin (G)

Waikato Hospital, Hamilton, New Zealand.

Richard Troughton (R)

Christchurch Heart Institute, University of Otago, Christchurch, New Zealand.

Carolyn S P Lam (CSP)

Cardiovascular Research Institute, National University Health System, Singapore.
National University Heart Centre Singapore, Singapore.

A Mark Richards (AM)

Cardiovascular Research Institute, National University Health System, Singapore.
Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Christchurch Heart Institute, University of Otago, Christchurch, New Zealand.

Robert N Doughty (RN)

Heart Health Research Group, University of Auckland, Auckland, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH